Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for KB407 in Cystic fibrosis. The expected timing is based on the latest available company guidance and may change.
CORAL-1 study. 1/2024- Initiated dosing in Cohort 2. 12/12/24- Safety data reported. 11/03/25:- Interim Cohort 3 CF data before YE 2025. 01/08/26:- Positive Cohort 3 interim data show robust CFTR expression; plan registrational CORAL-3 enrollment start in Q2 2026. 02/17/26:- CORAL-1 highest-dose cohort showed broad CFTR expression and good tolerability; still plan CORAL-3 enrollment start in H1 2026. 05/04/26:- FDA platform designation; new NCT05504837 24-week safety study; enrollment Q2 2026, results Q4 2026. 08/03/26:- Repeat-dose KB407 enrollment ongoing; interim results and FDA design alignment expected Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.